The North East and Yorkshire NHS Pharmaceutical Purchasing Consortium intends to establish a Framework Agreement for the supply of Unlicensed Aseptic Compounded Specials. The requirement will cover the provision of unlicensed aseptic compounded specials, including sterile ready-to-administer injectable and infusion products that are batch manufactured or otherwise aseptically prepared in accordance with applicable UK regulatory standards and Good Manufacturing Practice (GMP) requirements. Suppliers will be required to hold all relevant licences, authorisations and regulatory approvals necessary to manufacture and supply unlicensed medicines within the UK, together with the appropriate quality assurance and batch release arrangements. The Framework Agreement will provide participating NHS organisations with access to safe, compliant and competitively sourced unlicensed aseptic compounded products, supporting continuity of supply, product quality assurance, patient safety and value for money across the NHS.

Procurement Act 2023

Preliminary market engagement relating to this requirement was previously undertaken and notified under PME Notice Reference 2026/S 000-052214 in connection with the originally proposed Dynamic Market procurement route. The requirement, scope and anticipated market offering remain materially unchanged from those previously communicated to the market. The principal change is the decision to procure the requirement through a Framework Agreement rather than a Dynamic Market. As the Consortium considers that the previous engagement remains relevant and adequate in informing the procurement approach, no further separate programme of preliminary market engagement is currently proposed. This Preliminary Market Engagement Notice is therefore published to ensure transparency regarding the revised procurement strategy and to notify the market of the change in route.